Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TIGER: Nilotinib vs Nilotinib + IFN in CML
NCT01657604Phase 3Completed
- Sponsor
- Friedrich Schiller University Jena
- Start
- Aug 2012
- Primary completion
- May 2022
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 3
01
Overview
A Phase 3 trial of peginterferon alfa-2b in chronic myeloid leukemia (CML), sponsored by Friedrich Schiller University Jena. Started Aug 2012; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT01657604.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01657604.